These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35226739)

  • 1. The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
    Nakamura A; Grossman S; Song K; Xega K; Zhang Y; Cvet D; Berger A; Shapiro G; Huszar D
    Blood; 2022 May; 139(18):2770-2781. PubMed ID: 35226739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.
    Lightcap ES; Yu P; Grossman S; Song K; Khattar M; Xega K; He X; Gavin JM; Imaichi H; Garnsey JJ; Koenig E; Zhang H; Lu Z; Shah P; Fu Y; Milhollen MA; Hatton BA; Riceberg J; Shinde V; Li C; Minissale J; Yang X; England D; Klinghoffer RA; Langston S; Galvin K; Shapiro G; Pulukuri SM; Fuchs SY; Huszar D
    Sci Transl Med; 2021 Sep; 13(611):eaba7791. PubMed ID: 34524860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.
    Nakamura K; Casey M; Oey H; Vari F; Stagg J; Gandhi MK; Smyth MJ
    Leukemia; 2020 Oct; 34(10):2708-2721. PubMed ID: 32269319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
    Kumar S; Schoonderwoerd MJA; Kroonen JS; de Graaf IJ; Sluijter M; Ruano D; González-Prieto R; Verlaan-de Vries M; Rip J; Arens R; de Miranda NFCC; Hawinkels LJAC; van Hall T; Vertegaal ACO
    Gut; 2022 Nov; 71(11):2266-2283. PubMed ID: 35074907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
    Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
    Front Immunol; 2019; 10():1943. PubMed ID: 31475004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
    Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
    Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
    Kohrt HE; Thielens A; Marabelle A; Sagiv-Barfi I; Sola C; Chanuc F; Fuseri N; Bonnafous C; Czerwinski D; Rajapaksa A; Waller E; Ugolini S; Vivier E; Romagné F; Levy R; Bléry M; André P
    Blood; 2014 Jan; 123(5):678-86. PubMed ID: 24326534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.
    Lam V; Roleder C; Liu T; Bruss N; Best S; Wang X; Phillips T; Shouse G; Berger AJ; Alinari L; Wang L; Siddiqi T; Pennock ND; Danilov AV
    Mol Cancer Ther; 2023 Sep; 22(9):1040-1051. PubMed ID: 37420267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
    Kohrt HE; Houot R; Goldstein MJ; Weiskopf K; Alizadeh AA; Brody J; Müller A; Pachynski R; Czerwinski D; Coutre S; Chao MP; Chen L; Tedder TF; Levy R
    Blood; 2011 Feb; 117(8):2423-32. PubMed ID: 21193697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
    Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
    MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacytidine in preclinical models of acute myeloid leukemia.
    Gabellier L; De Toledo M; Chakraborty M; Akl D; Hallal R; Aqrouq M; Buonocore G; Recasens-Zorzo C; Cartron G; Delort A; Piechaczyk M; Tempé D; Bossis G
    Haematologica; 2024 Jan; 109(1):98-114. PubMed ID: 37608777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.
    Du J; Lopez-Verges S; Pitcher BN; Johnson J; Jung SH; Zhou L; Hsu K; Czuczman MS; Cheson B; Kaplan L; Lanier LL; Venstrom JM
    Cancer Immunol Res; 2014 Sep; 2(9):878-89. PubMed ID: 24958280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cells, particularly activated CD4
    Wang Z; Chimenti MS; Strouse C; Weiner GJ
    Cancer Immunol Immunother; 2022 Feb; 71(2):237-249. PubMed ID: 34110453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.
    Rafiq S; Butchar JP; Cheney C; Mo X; Trotta R; Caligiuri M; Jarjoura D; Tridandapani S; Muthusamy N; Byrd JC
    J Immunol; 2013 Mar; 190(6):2702-11. PubMed ID: 23418626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
    Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. slan
    Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
    Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
    Cheadle EJ; Lipowska-Bhalla G; Dovedi SJ; Fagnano E; Klein C; Honeychurch J; Illidge TM
    Leukemia; 2017 Jul; 31(7):1611-1621. PubMed ID: 27890931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
    Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
    Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.